News for Insulet Corporation (PODD)

Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company's Board of Directors, effective April 4, 2025. Mr. McMillan wa

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in [url="]tubeless insulin pump[/url] technology with its Omnipod® brand of pro

Insulet Corporation (NASDAQ: PODD) (”œInsulet” or the ”œCompany”), the global leader in tubeless insulin pump technology with its Omnipod® brand of prod

Insulet Corporation (NASDAQ: PODD) (”œInsulet” or the ”œCompany”), the global leader in tubeless insulin pump technology with its Omnipod® brand of prod

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in [url="]tubeless insulin pump[/url] technology with its Omnipod® brand of pro

Insulet Corporation (PODD) announces plans for a $450M notes offering and credit facility amendment.

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. The Omnipod 5 Autom…

Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on PODD stock here.

Insulet Corporation (PODD), a leading innovator in the medical device industry, has announced a significant leadership change within its technology division.

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income countries.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in [url="]tubeless insulin pump[/url] technology with its Omnipod® brand of pro

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more on PODD stock here.

Discover Insulet's 2024 earnings highlights, record revenues, and Omnipod 5 growth in diabetes care.

Insulet Corporation (NASDAQ:PODD) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsJune Lazaroff - Senior Director of...

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) reports strong Q4 results with $1.15 EPS and $597.5M revenue, exceeding estimates. Despite growth, shares fall 2.88%.

Stocks Analysis by Christine Short covering: S&P 500, Coca-Cola Co, McDonald’s Corporation, Akamai Technologies Inc. Read Christine Short's latest article on Investing.com

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.